Reneo Pharmaceuticals, Inc. RPHM
Set alert
18.20 +18.20 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 60.84M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -47.89
- Beta
- 0.22
- Short ratio
- 27.39
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 11, 2024
- 50-d avg
- 14.92
- 200-d avg
- 16.09
- 1y target
- 2.25
3M chart
Events in this range
- Aug 13, 2024Earnings: —; estimate -0.17; surprise —%
Signals (18)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Sep 25, 2024 | 2 years ago |
| SMA: Bullish | Sep 25, 2024 | 2 years ago |
| SMA: Bearish | Sep 23, 2024 | 2 years ago |
| SMA: Bearish | Sep 23, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 19, 2024 | 2 years ago |
| SMA: Bullish | Sep 18, 2024 | 2 years ago |
| SMA: Bullish | Sep 18, 2024 | 2 years ago |
| SMA: Bearish | Aug 30, 2024 | 2 years ago |
| MACD: Sell Signal | Aug 30, 2024 | 2 years ago |
| SMA: Bullish | Aug 29, 2024 | 2 years ago |
| SMA: Bearish | Aug 28, 2024 | 2 years ago |
| SMA: Bearish | Aug 28, 2024 | 2 years ago |
| SMA: Bullish | Aug 15, 2024 | 2 years ago |
| SMA: Bullish | Aug 14, 2024 | 2 years ago |
| MACD: Buy Signal | Aug 14, 2024 | 2 years ago |
| RSI: Oversold | Aug 7, 2024 | 2 years ago |
| MACD: Sell Signal | Aug 5, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 16, 2024 | 2 years ago |
Key statistics
- Market cap
- 60.84M
- Enterprise value
- -15.01M
- Trailing P/E
- 0.00
- Forward P/E
- -47.89
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.79
- EPS (TTM)
- -16.80
- Beta
- 0.22
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -43.42M
- Total cash
- 76.67M
- Total debt
- 823.00K
- Return on equity
- -54.00%
- Shares outstanding
- 3.34M
- Short % of float
- 17.56%
- 50-day average
- 14.92
- 200-day average
- 16.09
Analyst view
Consensus: hold
Hold
Price target (mean) 2.25 -87.6% downside
Now 18.20
- Target (low)
- 1.50
- Target (mean)
- 2.25
- Target (high)
- 3.00
Next earnings
Nov 11, 2024
Expected Nov 11, 2024. Consensus EPS estimate -0.07.
Financials — quick view
RPHM Revenue — quarterly 0
RPHM Net income — quarterly -5.36M
RPHM EPS — quarterly -0.16
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2024 | Sep 1, 2024 | -0.07 | — | — | — |
| Aug 13, 2024 | Jun 1, 2024 | -0.17 | — | — | — |
| May 7, 2024 | Mar 1, 2024 | -0.37 | — | — | — |
| Mar 28, 2024 | Dec 1, 2023 | -0.55 | — | — | — |
| Nov 13, 2023 | Sep 1, 2023 | -0.60 | — | — | — |
| Aug 10, 2023 | Jun 1, 2023 | -0.55 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 11, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 7, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 27, 2023 | HC Wainwright & Co. | init | — | Buy |
| Jul 2, 2023 | B of A Securities | init | — | Buy |
| May 17, 2022 | Piper Sandler | main | — | Overweight |
| Mar 23, 2022 | SVB Leerink | main | — | Outperform |
About Reneo Pharmaceuticals, Inc.
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- reneopharma.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on RPHM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GREY MICHAEL G. | Officer and Director | Stock Gift | Jul 25, 2023 | 628,846 |
| HALL ASHLEY | Officer | Conversion of Exercise of derivative security | Aug 27, 2023 | 39,600 |
| LEONARD BRADEN MICHAEL | Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 24, 2024 | 0 |
| NOVO HOLDINGS A/S | Beneficial Owner of more than 10% of a Class of Security | Sale | Jun 22, 2023 | 3,330,340 |
| ODONNELL NIALL | Director | Purchase | May 7, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| NEA Management Company, LLC | 14.16% | 4,785,494 | 31.39M | Jun 29, 2023 |
| Novo Holdings A/S | 9.85% | 3,330,377 | 21.85M | Jun 29, 2023 |
| Carlyle Group Inc. | 7.98% | 2,698,957 | 17.71M | Jun 29, 2023 |
| Rivervest Venture Management LLC | 7.50% | 2,534,220 | 16.62M | Jun 29, 2023 |
| Octagon Capital Advisors LP | 7.01% | 2,368,587 | 15.54M | Jun 29, 2023 |
| Eventide Asset Management LLC | 5.18% | 1,750,000 | 11.48M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund | 5.18% | 1,750,000 | 11.48M | Jun 29, 2023 |
| Vanguard Total Stock Market Index Fund | 1.76% | 596,113 | 3.91M | Jun 29, 2023 |
| Franklin Strategic Series-Franklin Biotechnology Discove | 1.27% | 429,233 | 3.45M | Jul 30, 2023 |
| Vanguard Extended Market Index Fund | 0.82% | 278,541 | 1.83M | Jun 29, 2023 |
| iShares Russell 2000 ETF | 0.54% | 184,091 | 1.11M | Aug 30, 2023 |
| Fidelity Small Cap Index Fund | 0.25% | 84,859 | 681.42K | Jul 30, 2023 |